Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has raised approximately $90 million through equity and debt financing over three years to build a diversified drug-development portfolio, leaving the biotechnology …
ICYMI: Medicus Pharma Faces Clinical Test After Raising $90 Million Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) is concentrating its drug-development investments on targeted cancer therapies while pursuing partnerships to limit future financing requirements, a strategic shift that follows …
Medicus Pharma Shifts Focus to Oncology Amid Stock Volatility Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has proposed a redesigned late-stage development program for its prostate cancer drug Teverelix that could reduce planned enrollment by about 60% while …
ICYMI: Medicus Seeks FDA Path to Cut Teverelix Trial by 60% Read More PHILADELPHIA, PA — Medicus Pharma Ltd. is seeking U.S. Food and Drug Administration approval for a redesigned late-stage development plan that could cut enrollment in its Teverelix advanced prostate cancer …
Medicus Seeks FDA Path to Cut Teverelix Trial by 60% Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) will end internally funded development of SkinJect for sporadic nodular basal cell carcinoma and concentrate its clinical spending on Gorlin syndrome, narrowing …
ICYMI: Medicus Narrows SkinJect Program to Gorlin Syndrome Read More PHILADELPHIA, PA — Medicus Pharma is ending further development of SkinJect for sporadic nodular basal cell carcinoma and concentrating its investment on an FDA-authorized Phase 2b study in Gorlin syndrome, …
Medicus Narrows SkinJect Program to Gorlin Syndrome Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) selected the 200-mcg dose of its SkinJect patch for further development after completing a Phase 2 basal cell carcinoma study, supporting the …
ISYMI: Medicus Picks 200-Mcg SkinJect Dose for Gorlin Program Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) is making precision oncology its primary development strategy, concentrating capital and clinical resources on the CD228V antibody-drug conjugate while seeking partnerships to …
Medicus Shifts Strategy to Precision Oncology With CD228V Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) received FDA authorization to begin an NDA-enabling Phase 2b study of SkinJect in patients with Gorlin Syndrome, advancing the company’s lead program …
FDA Clears Medicus SkinJect Study for Gorlin Syndrome Read More CONSHOHOCKEN, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) agreed Wednesday to pay Pfizer Inc. $27 million for worldwide rights to an early-stage antibody-drug conjugate, taking control of CD228V’s development while …
Medicus Pays $27 Million for Pfizer Cancer Drug Rights Read More